International Journal of Clinical Research

Objective To use thrombohemogram (TEG) to evaluate the changes of cerebral microhemorrhage focus and antiplatelet effect in patients with symptomatic new-onset subcortical infarction (CSVD). Methods 80 CSVD patients with symptomatic new subcortical infarction were taken as study subjects and randomly divided into group A and group B. 40 CSVD patients without new subcortical infarction were selected as the control group. In group A, oral aspirin enteropolated tablets, group B, and the control group did not use antiplatelet drugs. Patients in groups A and B underwent head MRI (MRI), magnetic sensitivity weighted imaging (SWI) and TEG examination before and 6 months after enrollment, while the control group only underwent head MRI and SWI examination before and after enrollment. Results There was no significant difference in the number of cerebral microbleeding lesions in the three groups. Groups A and B were from the control group and the control group. After group A and B, R and K values of TEG parameters were higher than before treatment, and α angle and MA values were lower than before treatment. There was no difference in the efficacy of platelet inhibition rate between patients in groups A and B. By comparison between the three groups in group A and B were good, effective, ineffective or ineffective, or ineffective in group A and group B, there was no significant difference in the increase of cerebral microhemorrhage lesions. Conclusion There was no significant difference in antiplatelet aggregation effect between aspirin enteric-coated tablets and clopidogrel sulfate tablets in the secondary prevention of CSVD, but both may promote the occurrence of cerebral microbleeding foci, and different platelet inhibition rates were not significantly associated with the increase of cerebral microbleeding foci.

Thromboelogram; Cerebral small vascular disease; Cerebral microhemorrhage